High-risk of recurrence for nodal micrometastasis with breast pathologic complete response (ypT0/Tis ypN1mi) after neoadjuvant chemotherapy.

被引：0
|
作者：
Garcia Torralba, Esmeralda
de la Morena, Pilar
Garcia Gomez, Marina
Ivars Rubio, Alejandra
Garcia Martinez, Elena
Garcia-Garre, Elisa
Martinez Galvez, Maria
Marin Zafra, Gema
Aguilar Jimenez, Jose
Navarro Manzano, Esther
Ayala, Francisco
机构：
[1] Hosp G Univ Morales Meseguer, Dept Hematol & Med Oncol, IMIB Arrixaca, Murcia, Spain
[2] Univ Murcia, Murcia, Spain
[3] Hosp G Univ Morales Meseguer, Dept Radiol, Murcia, Spain
[4] Hosp G Univ Morales Meseguer, Dept Surg, UMU, IMIB Arrixaca, Murcia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12524
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pattern of recurrence after pathologic complete response after neoadjuvant chemotherapy in patients with early HER2-positive breast cancer: Real-world evidence
    Kim, Jee Hung
    Lee, Jii Bum
    Bae, Soong Joon
    Ahn, Sung Gwe
    Jeong, Joon
    Kim, Min Hwan
    Kim, Seul-Gi
    Kim, Gun Min
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Park, Byeong Woo
    Kim, Seung Il
    Sohn, Joohyuk
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [42] Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model
    Jang, Hyo Joon
    Cho, Sukki
    Kim, Kwhanmien
    Jheon, Sanghoon
    Yang, Hee Chul
    Kim, Dong Kwan
    [J]. CANCER RESEARCH AND TREATMENT, 2017, 49 (04): : 898 - 905
  • [43] The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Blumencranz, Peter
    Habibi, Mehran
    Shivers, Steve
    Acs, Geza
    Blumencranz, Lisa E.
    Yoder, Erin B.
    van der Baan, Bastiaan
    Menicucci, Andrea R.
    Dauer, Patricia
    Audeh, William
    Cox, Charles E.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (13) : 8353 - 8361
  • [44] Pathologic response rate for high-risk operable breast cancer after TNCF semi-intensive neoadjuvant chemotherapy: Updated data with long-term results.
    Durando, X.
    Cure, H.
    Abrial, C.
    Goldschmidt, E.
    Penault-Llorca, F.
    Van Praagh-Doreau, L.
    Pomel, C.
    Machover, D.
    Chollet, P. J.
    Mouret-Reynier, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Peter Blumencranz
    Mehran Habibi
    Steve Shivers
    Geza Acs
    Lisa E. Blumencranz
    Erin B. Yoder
    Bastiaan van der Baan
    Andrea R. Menicucci
    Patricia Dauer
    William Audeh
    Charles E. Cox
    [J]. Annals of Surgical Oncology, 2023, 30 : 8353 - 8361
  • [46] Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy
    Qian, Xiaoyan
    Xiu, Meng
    Li, Qing
    Wang, Jiayu
    Fan, Ying
    Luo, Yang
    Cai, Ruigang
    Li, Qiao
    Chen, Shanshan
    Yuan, Peng
    Ma, Fei
    Xu, Binghe
    Zhang, Pin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted?
    Parvez, Elena
    Muanza, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for advanced breast cancer patients with high risk for Hereditary Breast and Ovarian Cancer Syndrome (HBOC).
    Sant'Ana, Rosane Oliveira
    de Lima Silva-Fernandes, Isabelle Joyce
    dos Santos Luciano, Maria Claudia
    de Barros Silva, Paulo Goberlanio
    Alves Lima, Marcos Venicio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy
    Kang, S.
    Lee, S. H.
    Lee, H. J.
    Jeong, H.
    Jeong, J-H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Gong, G.
    Kim, H. H.
    Lee, S.
    Lee, J.
    Kim, S-B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S624 - S624
  • [50] Regional Nodal Irradiation in Breast Cancer Patients With Clinical N1 and Pathologic N0 Disease After Neoadjuvant Chemotherapy: An Analysis of the National Cancer Data Base
    Vu, C. C.
    Sura, K.
    Chen, P. Y.
    Dilworth, J. T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E4 - E5
12345